2021 European Society for Medical Oncology Congress Coverage

Every year, the European Society for Medical Oncology Congress brings together clinicians, researchers, and advocates to discuss the latest cancer study results. We’re proud to present our coverage below.

Adding Keytruda to Chemotherapy Improves Overall Survival in Metastatic, Strongly PD-L1-Positive Triple-Negative Breast Cancer

Long-Term Side Effects Reduce Quality of Life Years After Cancer Diagnosis

Experimental Vic-Trastuzumab Duocarmazine Better Than Doctors’ Treatment Choices for Pre-treated Advanced-Stage HER2-Positive Breast Cancer

Adding Kisqali to Femara Improves Overall Survival for Postmenopausal Women With Advanced-Stage Hormone-Receptor-Positive HER2-Negative Breast Cancer

After 2-3 Years of Tamoxifen, 5 Years of Femara Offers More Benefits Than 2-3 Years

Enhertu Dramatically More Effective Than Kadcyla as Second Treatment for Metastatic HER2-Positive Breast Cancer

Adding Carboplatin to Chemotherapy Before Surgery Improves Early-Stage Triple-Negative Breast Cancer Outcomes

Breast Cancer Research at ESMO 2021, with Brian Wojciechowski, MD

Keytruda Added to Chemotherapy Improves Overall Survival for Metastatic PD-L1-Positive, Triple-Negative Breast Cancer, with Hope Rugo, MD

Kisqali Plus Femara Seems Best Option for Advanced-Stage Hormone-Receptor-Positive HER2-Negative Breast Cancer, with Gabriel Hortobagyi, MD